Here are the 10-K annual reports from BioRegenx Inc (BRGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BRGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRGX filings page.
BioRegenx, Inc. develops medical test equipment, AI-driven telehealth technologies and science-based nutritional products sold to healthcare professionals and consumers. In 2025, net sales were $1.85 million, down from $2.34 million in 2024, mainly due to product issues with its medical testing platform that reduced distributor activity.
The company reported a 2025 net loss of $1.54 million, a sharp improvement from a $23.05 million loss in 2024, largely because 2024 included heavy impairment and amortization charges. Despite this, BioRegenx ended 2025 with stockholders’ deficit of $4.54 million, cash of $69,383, and notes payable of about $1.19 million plus $1.03 million of related-party loans, with $522,500 of notes in default.
Management and the auditors state there is substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative equity, limited liquidity and debt defaults. Operations span microvascular health products, AI-based remote diagnostics through DocSun, wellness supplements via MyBodyRx and NuLife, and the Findit AI Connect digital marketing platform.